Value through Innovation27 July 2016

Clinical Study Results

  • MICARDIS ® - Obesity, Insulin Resistance
    Clinical Study Number 502.469
    Study Indication Obesity, Insulin Resistance
    Product MICARDIS ®
    Generic Name Telmisartan
    Lab Code
    Clinical Phase II
    Study Title

    A randomised, double-blind, placebo-controlled, parallel group, 16-week MICARDIS® (160 mg) tablets, proof-of-concept study, evaluating insulin sensitivity in overweight or obese, non-diabetic, normotensives, using the oral glucose tolerance test, with a clamp sub-group

    Study Document Trial synopsis 502.469_DR english

Clinical Trial Registry and structured study results. Find here protocol information for all clinical study types.

European Trial Register of EU studies.